Showing 312 results
February 2014
-
Media ReleaseBulgaria approves Sandoz’s Airflusal® Forspiro®Holzkirchen, Germany, February 4, 2014 - Sandoz announced today it has received Bulgarian marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD…
-
Media ReleaseSandoz recognizes World Cancer Day 2014February 4, 2014 - Today Sandoz recognizes World Cancer Day. Cancer is a leading cause of death worldwide, accounting for 7.6 million deaths (around 13% of all deaths) in 2008, according to the World…
January 2014
-
Media ReleaseRomania approves Sandoz’s Airflusal® Forspiro®Holzkirchen, Germany, January 29, 2014 - Sandoz announced today it has received Romanian marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD…
-
Media ReleaseNovartis announces Q4/Full Year 2013 resultsBasel, January 29, 2014 - Novartis delivers strong sales and innovation in 2013; underlying business performance reinforces growth prospects.
-
Media ReleaseNovartis recognized among world's most sustainable companies in Corporate Knights Global 100Basel, January 27, 2014 - Novartis is pleased to announce that it has been named among the 2014 Corporate Knights Global 100. Corporate Knights announced the results of its 2014 Global 100 Most…
-
Media ReleaseSandoz launches Airflusal ® Forspiro® in DenmarkCopenhagen, January 20, 2014 - Sandoz announces that it is launching in Denmark today AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary…
-
Media ReleaseHungary approves Sandoz’s Airflusal® Forspiro®Holzkirchen, Germany, January 16, 2014 - Sandoz announced it has received marketing authorization in Hungary for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.…
-
Media ReleaseSweden approves Sandoz’s Airflusal® Forspiro®Holzkirchen, Germany, January 14, 2014 - Sandoz announced today it has received Swedish marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD…
-
Media ReleaseGermany approves Sandoz’s Airflusal® Forspiro®Holzkirchen, Germany, January 13, 2014 - Sandoz announced today it has received German marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.…
-
Media ReleaseNovartis publishes Corporate Responsibility OverviewJanuar 08, 2014 - Novartis recently published a comprehensive overview of its Corporate Responsibility strategy and programs. Learn more (PDF 743 KB)
-
Media ReleaseSandoz biosimilar filgrastim recommended for approval by FDA Oncologic Drugs Advisory CommitteeOncologic Drugs Advisory Committee (ODAC) votes in favor of recommending biosimilar filgrastim for approval in the US Biosimilar filgrastim recommended to be approved for use in all requested…